Author of

• 12648

  +

  P3.11 - Poster Session 3 - NSCLC Novel Therapies (ID 211)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12699

    +

    P3.11-051 - VEGFRs predict bevacizumab benefit in advanced non small cell lung cancer patients (ID 2333)

    09:30 - 09:30  |  Author(s): R. Cao
    • Abstract

    Background
    Bevacizumab is reported to produce clinical benefit in advanced non-squamous non-small-cell lung cancer (NSCLC) patients when combined with chemotherapy. However, no biological markers have been identified for patient selection of bevacizumab treatment.

    Methods
    We describe an ongoing observational study in patients with advanced non-squamous NSCLC patients. Patients with metastatic disease will be recruited to receive chemotherapy plus bevacizumab 15 mg/kg for 4-6 cycles and radiotherapy when necessary. VEGF-A、VEGFR-1、VEGFR-2 levels in peripheral blood of patients will be tested before and after the bevacizumab treatments. Cycles are 3 weeks.The primary endpoint is progression-free survival (PFS) without grade 4 toxicity. The secondary endpoint is overall survival (OS). The study will enroll 40 patients approximately. The relationship between VEGF-A、VEGFR-1、VEGFR-2 levels and the effect of treatment will be evaluated.

    Results
    no

    Conclusion
    This study will provide results on biomarker options for patient selection of bevacizumab treatment. Correspondence to Li Liu, E-mail: [email protected]